Phospho-CTNNA1 (Ser641) Antibody

What is CTNNA1 and what is the significance of its phosphorylation at Ser641?

CTNNA1, also known as α-E-catenin, is a key component of the cadherin-catenin complex that associates with the cytoplasmic domain of various cadherins. This complex links to the actin filament network and is critical for cell-adhesion properties. Phosphorylation at serine 641 (Ser641) represents a post-translational modification that regulates CTNNA1 function. The phosphorylation state at this specific residue modulates the protein's interaction with binding partners and potentially influences its role in cell differentiation and adhesion processes .

How do CTNNA1 and its phosphorylation status relate to human diseases?

Recent research has established CTNNA1 as a potential risk gene for diffuse gastric cancer. Loss-of-function (LOF) variants in CTNNA1 have been detected in individuals with gastric and breast cancers. In a large study of over 151,000 individuals, approximately 0.03% carried CTNNA1 LOF variants, with 12% of carriers having diffuse gastric cancer and 67% having breast cancer . Immunohistochemistry analyses demonstrate decreased α-E-catenin expression in gastric cancers from these individuals, suggesting that alterations in CTNNA1 function, potentially including changes in phosphorylation status, contribute to cancer pathogenesis .

What are the common applications for Phospho-CTNNA1 (Ser641) antibodies in research?

Phospho-CTNNA1 (Ser641) antibodies are primarily used in ELISA and Western blot (WB) applications at recommended dilutions of 1:500-1:1000 for WB . These antibodies enable researchers to specifically detect the phosphorylated form of CTNNA1 at serine 641, allowing for investigation of signaling pathways, post-translational modifications, and protein-protein interactions. Such applications are particularly valuable in studies examining cell adhesion mechanisms, cancer cell biology, and the role of CTNNA1 in disease processes.

How does phosphorylation at Ser641 alter CTNNA1's interaction with the cadherin-catenin complex and the actin cytoskeleton?

Phosphorylation of CTNNA1 at Ser641 may modulate its binding affinity for other components of the cadherin-catenin complex and potentially regulate its interaction with the actin cytoskeleton. Research indicates that CTNNA1 plays a crucial role in linking the cadherin-catenin complex to the actin filament network, which is essential for cell-adhesion properties . Several seminal studies, including those by Drees et al. (2005) and Yamada et al. (2005), have elucidated the mechanisms by which α-catenin mediates these interactions . When investigating these interactions using Phospho-CTNNA1 (Ser641) antibodies, researchers should consider using co-immunoprecipitation experiments followed by Western blot analysis to assess how phosphorylation status affects protein-protein interactions within this complex.

What are the specific signaling pathways that regulate CTNNA1 phosphorylation at Ser641, and how does this modification affect downstream cellular processes?

The specific kinases and phosphatases that regulate CTNNA1 phosphorylation at Ser641 remain an active area of investigation. Research by Hwang et al. (2005) provided initial insights into signaling mechanisms affecting α-catenin . To investigate these pathways, researchers can design experiments using kinase inhibitors or activators followed by Western blot analysis with Phospho-CTNNA1 (Ser641) antibodies. Additionally, site-directed mutagenesis studies creating phospho-null (S641A) or phospho-mimetic (S641D/E) mutations can help elucidate the functional consequences of this modification on cell adhesion, migration, and differentiation.

How do CTNNA1 mutations and phosphorylation status intersect in cancer development and progression?

The relationship between CTNNA1 mutations and its phosphorylation status in cancer development represents a complex interplay that merits further investigation. Evidence indicates that CTNNA1 LOF variants are associated with diffuse gastric cancer and breast cancer . In families with CTNNA1 mutations, immunohistochemistry analysis reveals decreased α-E-catenin expression in gastric cancers . A particularly significant finding is that prophylactic total gastrectomy in an asymptomatic CTNNA1 mutation carrier revealed diffuse gastric cancer foci with loss of catenin alpha-1 expression, even after normal upper endoscopy results . This suggests that CTNNA1 behaves similarly to CDH1 (E-cadherin) in cancer development, with implications for phosphorylation-dependent regulation of protein function.

What are the optimal conditions for using Phospho-CTNNA1 (Ser641) antibodies in Western blot analyses?

For optimal Western blot analysis using Phospho-CTNNA1 (Ser641) antibodies, researchers should:

• Use fresh cell or tissue lysates prepared with phosphatase inhibitors to preserve phosphorylation states

• Apply the antibody at dilutions between 1:500-1:1000

• Include appropriate positive and negative controls (including phosphatase-treated samples)

• Consider using phospho-specific protein standards for accurate molecular weight determination

• Employ enhanced chemiluminescence (ECL) detection for optimal sensitivity

When troubleshooting, ensure complete transfer of high molecular weight proteins (CTNNA1 is approximately 102 kDa), optimize blocking conditions to reduce background, and validate specificity using competing phosphopeptides.

How can researchers validate the specificity of Phospho-CTNNA1 (Ser641) antibodies for their experimental systems?

Validating antibody specificity is crucial for reliable research outcomes. For Phospho-CTNNA1 (Ser641) antibodies, researchers should:

• Compare reactivity in samples with and without phosphatase treatment

• Utilize competing peptide blocking with both phosphorylated and non-phosphorylated peptides

• Employ knockout or knockdown systems as negative controls

• Compare results across multiple detection methods (Western blot, ELISA, immunofluorescence)

• Consider using phospho-null mutants (S641A) as specificity controls

High-quality Phospho-CTNNA1 (Ser641) antibodies should be purified using affinity chromatography with epitope-specific phosphopeptides, with non-phospho specific antibodies removed through chromatography .

What sample preparation techniques preserve the phosphorylation state of CTNNA1 at Ser641?

Preserving phosphorylation states requires careful sample handling:

• Rapidly harvest and freeze samples to prevent phosphatase activity

• Include multiple phosphatase inhibitors in lysis buffers (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate)

• Maintain samples at cold temperatures throughout processing

• Consider using direct lysis in SDS sample buffer for immediate denaturation

• Process samples consistently across experimental conditions to enable valid comparisons

For immunoprecipitation applications, use non-denaturing lysis conditions that maintain protein-protein interactions while preserving phosphorylation status.

How can Phospho-CTNNA1 (Ser641) antibodies be used to investigate the role of CTNNA1 in diffuse gastric cancer?

Researchers investigating CTNNA1's role in diffuse gastric cancer can employ Phospho-CTNNA1 (Ser641) antibodies in multiple approaches:

• Comparative analysis of phosphorylation levels between normal gastric tissue and diffuse gastric cancer specimens

• Correlation studies between phosphorylation status and clinical outcomes

• Investigation of signaling pathways affected by CTNNA1 LOF variants

• Immunohistochemical analysis to examine spatial distribution of phosphorylated CTNNA1 in tissue microarrays

Recent studies have identified CTNNA1 as a potential diffuse gastric cancer risk gene, with LOF variants detected in 0.03% of individuals undergoing multigene panel testing . Of 33 CTNNA1 LOF carriers with detailed history, 12% had diffuse gastric cancer, and 21% of families reported a history of gastric cancer . These findings provide a foundation for further research into the functional consequences of CTNNA1 phosphorylation in cancer development.

What is the current evidence for using CTNNA1 phosphorylation status as a biomarker in cancer diagnosis or prognosis?

The potential of CTNNA1 phosphorylation status as a cancer biomarker remains preliminary but promising:

• Decreased α-E-catenin expression has been observed in gastric cancers from individuals with CTNNA1 mutations

• The CTNNA1 c.1351C>T nonsense variant has been identified in multiple families with early-onset diffuse gastric cancer or breast cancer

• Prophylactic gastrectomy specimens from asymptomatic CTNNA1 mutation carriers have revealed diffuse gastric cancer foci with loss of catenin alpha-1 expression

How does the study of CTNNA1 phosphorylation inform potential therapeutic approaches for cancers associated with CTNNA1 mutations?

Understanding CTNNA1 phosphorylation may inform novel therapeutic strategies:

• Targeting kinases or phosphatases that regulate CTNNA1 Ser641 phosphorylation

• Developing approaches to restore normal CTNNA1 function in the context of LOF mutations

• Identifying synthetic lethal interactions in cells with altered CTNNA1 function

How do antibodies against Phospho-CTNNA1 (Ser641) compare with those targeting other phosphorylation sites on CTNNA1?

While Phospho-CTNNA1 (Ser641) antibodies specifically detect phosphorylation at serine 641, researchers should consider how this modification compares with other phosphorylation sites on CTNNA1. Different phosphorylation sites may regulate distinct aspects of CTNNA1 function, potentially affecting different protein-protein interactions or cellular processes. When designing comprehensive studies of CTNNA1 regulation, researchers should consider including antibodies targeting multiple phosphorylation sites to develop a complete understanding of how post-translational modifications regulate this protein's function in normal and disease states.

What are the relative advantages of using Phospho-CTNNA1 (Ser641) antibodies versus total CTNNA1 antibodies in cancer research?

Research approaches using both phospho-specific and total CTNNA1 antibodies offer complementary information:

For optimal results, researchers should employ both antibody types in parallel to determine both expression levels and phosphorylation status, particularly when investigating cancer samples where both may be altered.

What are the current knowledge gaps regarding CTNNA1 phosphorylation at Ser641?

Despite progress in understanding CTNNA1 function, several knowledge gaps remain regarding its phosphorylation at Ser641:

• The specific kinases and phosphatases regulating this modification

• The temporal dynamics of phosphorylation during cell adhesion, migration, and division

• How phosphorylation affects CTNNA1's mechanosensing properties

• The interplay between different post-translational modifications on CTNNA1

• How CTNNA1 phosphorylation patterns differ across tissue types and disease states

Addressing these gaps will require creative experimental approaches combining biochemical, cell biological, and genetic techniques with advanced imaging methods to capture both spatial and temporal aspects of CTNNA1 regulation.

What emerging technologies might enhance the study of CTNNA1 phosphorylation in the future?

Emerging technologies that may advance our understanding of CTNNA1 phosphorylation include:

• Phospho-proteomics approaches to identify comprehensive phosphorylation patterns

• Live-cell imaging with phospho-specific biosensors to track dynamic changes

• CRISPR-based genomic engineering to create endogenously tagged CTNNA1 variants

• Single-cell analyses to capture heterogeneity in phosphorylation status

• Structural biology approaches to determine how phosphorylation alters protein conformation